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Abstract: The biochemical properties of erythrocyte or human red blood cell (RBC) membrane
acetylcholinesterase (AChE) and its applications on laboratory class and on research are reviewed.
Evidence of the biochemical and the pathophysiological properties like the association between
the RBC AChE enzyme activity and the clinical and biophysical parameters implicated in several
diseases are overviewed, and the achievement of RBC AChE as a biomarker and as a prognostic
factor are presented. Beyond its function as an enzyme, a special focus is highlighted in this review
for a new function of the RBC AChE, namely a component of the signal transduction pathway of
nitric oxide.
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1. Introduction
Erythrocytes or red blood cells (RBC) are more than sacks of oxyhemoglobin or deoxyhemoglobin
during the semi-life of 120 days in blood circulation [1]. Erythrocytes comport different signaling
pathways which includes the final stage of apoptosis, also called eryptosis [2,3]. Exovesicules enriched
with acetylcholinesterase (AChE) originated from membranes of aged erythrocytes appear in
plasma [4]. Kinetic changes of the AChE enzyme have been observed in old erythrocytes [5].
Previously, AChE in erythrocytes was evidenced as a biomarker of membrane integrity [6]. Later on,
increased impairment values of AChE enzyme activities were observed in several diseases as will be
described below.
The blood physiological functions at macro- and microcirculatory vessel networks are dependent
on RBCs’ membrane integrity and the normal interaction with endothelium and other blood
components [7]. Luminal vascular endothelial cells can rest in a stationary phase or be activated
during an inflammatory response. The degree of resolution of that response creates a solved acute
inflammation or unsolved chronic inflammation. In all situations, erythrocytes are a player [8].
Depending on the degree of endothelium integrity, the plasma acetylcholine (ACh) induces
vasodilation or vasoconstriction through the amount of nitric oxide (NO) synthesized by endothelial
cells and released to the vessels smooth muscle [9,10]. The NO released from endothelial cells
to the lumen is scavenged by the erythrocytes through the band 3 protein, providing a route for
an NO influx to, and an efflux from, erythrocytes [11–13]. NO is rescued by the hemoglobin
molecule forming S-nitrosohemoglobin (SNOHb) inside the erythrocyte [12,13]. In blood circulation,
where the erythrocyte senses tissues with low partial oxygen pressure, NO is transferred from β3
SNOHb to the thiol group of band 3 with an NO efflux to the lumen vessel [13]. Using in vitro
inhibitors of protein tyrosine kinase (PTK) and protein tyrosine phosphatase (PTP), phosphorylation
and dephosphorylating of band 3 at tyrosine residues have been evidenced and the two forms
exist in a dynamic equilibrium [14]. Dephosphorylate erythrocyte membrane band 3 is associated
with oxyhemoglobin and with the glycolytic enzymes, glyceraldehyde dehydrogenase, aldolase,
and phosphofructokinase, which disclose to the cytosol under phosphorylation band 3 state [15].
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A higher erythrocyte aggregation tendency and increased membrane AChE enzyme activity is also
evidenced when band 3 is phosphorylated, but not when it is dephosphorylated [16,17]. In addition,
glutathione is an abundant molecule inside erythrocytes, which has a thiol group that can react
with NO, forming nitrosothiols such as S-nitrosoglutathione (GSNO) [18]. The NO reservoir property
attributed to glutathione might be influenced by the inactivation of glutathione reductase induced by
the oxidative stress installed in erythrocytes [19].
Attempting to pursue the challenge of finding a physiological function for erythrocyte
membrane AChE, the nitric oxide discovery triggered by plasma ACh gave us a clue about the
action of AChE. Erythrocyte membrane AChE is involved in the nitric oxide (NO) signal pathway
as evidenced, for the first time at the start of this century, in several in vitro studies using blood samples
from healthy donors as described below.
2. Biochemical Properties of Human Erythrocyte Membrane Acetylcholinesterase
Human erythrocyte acetylcholinesterase (AChE) discovered by Alles and Haves in 1940 was later,
in 1961, classified as EC.3.1-1.7 by the Enzyme Commission [20,21]. Only in 1975 the appropriate process
of extraction and purification of the erythrocyte membrane AChE confirmed it as a glycoprotein [22].
Later in 1985 it was shown that this enzyme, located in the external leaflet of the erythrocyte membrane,
is a dimeric protein [23]. The catalytic efficiency of the dimeric form of AChE depends on the amphipathic
medium of extraction and purification [24,25]. AChE belongs to the glycosylphosphatidylinositol
(GPI)-anchored protein family and bears the Yta blood group antigen [26,27].
The kinetic profile of AChE shows a bell-shape curve, (Figure 1) [24], meaning that the enzyme-free,
enzyme substrate complex and the acyl enzyme intermediate form all exist in the reaction medium;
AChE is uncompetitive, inhibited by the excess of substrate concentration which has been shown also by
others authors [28]. This mechanism showed a second substrate molecule binding to the free anionic
group of the active center of the acyl enzyme complex [24]. The optimum substrate concentrations values,
which result from the velocity curve profile, are dependent on the native, solubilized, or purified forms
of the enzyme, of the ionic strength of the medium and pH values and of the type and concentration of
inhibitor or activator compounds [24]. Another parameter influent on optimum substrate values is the
method applied for the kinetic evaluation according to the product, thiocholine or acetate, that needs to
be measured when acetylthiocholine is used as the synthetic analog of acetylcholine (ACh), the natural
substrate of AChE [24,29]. A lower affinity constant for the substrate and a higher optimal substrate
concentration value are obtained at high ionic strength in relation to the lower ionic strength of the buffer
medium [24].
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least square method to the velocity equation coupled with the iterative non-linear method [24]. 
Figure 1. Bell-shape curve of enzymatic hydrolysis of hydrolysis of acetylthiocholine (ASCh) by AChE
purified from human erythrocytes indicate the inhibition of the reaction by the substrate. Applying the
Ellman’s method, AChE 0.04 IU/mL was added to preincubated for 10 min, at 25 ◦C, in 1 mL assay
solutions with 100 mM PO4 buffer, pH 8.0, and 0.2 mM DTNB [5,5-dithiobis(2-nitrobenzoic acid)]
before adding the sub trate at 0.0025 to 6 mM final concentratio s. All xperiments wer repeated
three times, and similar results were obtained. All the values obtained above 1 mM of ASCh were
diminished with those obtained in non-enzymatic hydrolysis. All data were analyzed applying the
least square method to the velocity equation coupled with the iterative non-linear method [24].
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The decrease of acylation velocity constant values with increased substrate concentrations were
obtained by a stopped-flow technique at low ionic strength using the purified form of human
erythrocyte AChE, thus confirming an uncompetitive inhibition by the substrate [30]. Due to the high
AChE enzyme activity at high ionic strength, the stopped-flow technique cannot be applied in the
transient phase of the acylation reaction [30].
Later, the same bell-shape kinetic profile curve was observed in krait venom AChE, the inhibition
by substrate concentration being reduced using a high ionic strength buffer in relation to low
ionic strength, as has been described for human erythrocyte AChE [24,31].
Large amounts of AChE are present in erythrocyte membrane exovesicles [32,33]. A biochemistry
laboratory practice for students, based on phthalate gradient concentrations was described using
erythrocyte suspensions to obtain aggregates of exovesicles, which are characterized by AChE
enzyme activity, protein, and phospholipids coloration processes [33]. This laboratory experimentation
matches objectives with teaching and learning activities in biochemistry courses [33]. The same
experimental protocol when used in erythrocyte suspensions under the presence of the membrane
fluidity fluorescent probes (diphenylhexatriene) DPH or trimethylamino-dipheny-lhexatriene
(TMA-DPH) or heptadecyl-hydroxycoumarin (C17-HC) showed the presence of exovesicles in all
the supernatants, confirmed by the AChE enzyme activity that is higher in those incubated with the
hydrophobic probe DPH in relation to the others amphiphilic TMA-DPH and C17-HC [34]. At variance,
the intensity and fluorescence anisotropy is higher in TMA-DPH and C17-HC supernatants vesicles in
relation to those obtained from the DPH [34]. Therefore, amphiphilic probes TMA-DPH and C17-HC
are preferentially incorporated in the exovesicles when compared with DPH [34]. The exovesiculation
process can, for example, occurs during the transformation of discocyte to stomatoscyte shape in the
presence of certain types of therapeutic drugs and oxidative stress [35,36]. Mathematical modeling
applied to those switch RBC forms can contribute to understanding, in patients under drug therapy,
the biorheogical behavior of RBCs in tissue oxygenation [37]. RBCs’ AChE enzyme activity and osmotic
fragility assessment are valuable for testing the cytotoxicity degree of lipophilic drugs that may disrupt
cellular membranes beyond their final usefulness, for example, as a cell nucleus target [6].
3. Implications of Erythrocyte Membrane Acetylcholinesterase Enzyme Activity in Disease
In 1973 erythrocyte AChE enzyme activity was reported as a marker of membrane integrity [38].
Changes in RBC AChE enzyme activity were evidenced in health and disease states. Reduced
erythrocyte AChE activity in aged humans and in neonates related to adult man was evidenced [5,38].
Sub-fractions of RBCs of different ages, prepared in vitro, showed that the oldest RBCs present an
AChE enzyme activity that is lower than the young RBC subpopulations, erythrocyte AChE being
considered a biomarker of aging [39]. Increased RBC AChE enzyme activity has been evidenced in
blood samples taken from healthy females [40].
In healthy females, adrenaline decreases AChE activity when α- and β-adrenergic receptors are
blocked and an inverse significant correlation between erythrocyte membrane rigidity and AChE
activity has also been registered. In erythrocytes from healthy males, adrenaline increases AChE
activity when no adrenergic receptors are blocked [5]. An opposite profile of erythrocyte membrane
fluidity under an adrenaline effect was observed in relation to that obtained in AChE activity in both
genders [5]. Peripheral blood from males and females has shown echinocytes when adrenaline is
present [5].
The discovery of sex-related differences in erythrocyte AChE activity and in the membrane
hydrophobic region fluidity under the adrenaline influence can contribute to understanding
different responses, attitudes, and behaviors with respect to stress situations, usually verified in
both genders. The existence of certain gender characteristics, at the cellular level, has important
implications in disease and medication responses.
Lower RBC AChE enzyme activity among farmers exposed to pesticides has been reported [41].
A recent evaluation of longitudinal changes of AChE and paraoxonase-1 enzyme activities in
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greenhouse workers, over a crop season, reveals that the decrease in RBC AChE results from an indirect
effect of pesticides, generating oxidant molecules, inducing lipid peroxidation, and consequently
interfering with the erythrocyte membrane’s integrity [41,42].
Patients with paroxysmal nocturnal hemoglobinuria and others with hemolytic anemia have been
characterized by lower levels of erythrocyte AChE [5].
In non-insulin diabetes mellitus patients undergoing routine angiography, an impairment in
RBC AChE enzyme activity and a lower fluidity in the hydrophobic erythrocyte membrane domain
after fluorescein injection was verified [43]. The less active state of AChE probably results from
conformational molecular changes occurring in AChE due to its tail insertion nearby or on high rigidity
membrane domains [43].
Ex vivo studies using blood samples obtained from patients suffering different diseases,
namely Parkinson, essential hypertension, glaucoma, retinal vasculitis, amyotrophic lateral sclerosis
(ALS), and Hirschsprung’s disease, have evidenced augmented levels of RBC AChE enzyme
activity [44–49]. Erythrocyte AChE is considered a biomarker of essential hypertension, glaucoma, ALS,
neurotoxicity, and pesticide poisoning and a diagnostic marker in Hirschsprung’s disease [45,46,48–52].
Higher AChE enzyme activity in RBCs were verified in glaucoma, essential hypertension, and ALS,
which are inflammatory vascular diseases characterized by a presence in the blood of high inflammatory
molecule concentrations, reactive oxygen species, and reactive nitrogen species [45,46,49,50,53,54].
Consequently, erythrocyte AChE is considered a marker of inflammation [54–56]. The modulation of
AChE enzyme activity by its natural substrate acetylcholine or by a strong inhibitor, such as velnacrine,
showed ACh with an anti-inflammatory effect characterized by its protective action before inflammation
development [56]. These anti-inflammatory characteristics of ACh were observed in vivo, by intravital
microscopy, in an experimental animal model, by the quantification of pro-inflammatory cytokines
production and by the visualization and quantification of leukocyte recruitment which includes the
number of rolling and adherent leukocytes and their rolling velocities [55].
4. Enrolment of Erythrocyte AChE in the Signal Transduction Pathway of Nitric oxide
Vascular endothelial cells change its phenotypes to participate in the acute inflammation,
which involves a faster or slower response in close relation to white blood cells [57]. Fibrinogen and
the ACh levels among other inflammatory molecules increase in plasma [58,59].
It has been shown in vitro that erythrocytes, in the presence of ACh, the natural substrate of the
membrane AChE, are able to release NO, which can be quantified by an amperometric method with
an amiNO-sensor [8,60]. It was also verified that the AChE–ACh enzyme active complex activates
the protein kinase C (PKC), which phosphorylates the protein tyrosine kinase (PTK) transforming
it from an inactive to an active state by covalent modulation (Figure 1) [61,62]. The amount of NO
is reinforced by calpeptin, a PTP inhibitor (Figure 1) [61]. PTK phosphorylates membrane band
3 protein, which becomes able to receive NO in its thiol group from S-nitrosohemoglobin molecules,
allowing the efflux of NO from erythrocytes [61]. Erythrocyte PKC phosphorylates protein
tyrosine phosphatase (PTP) and PI3K phosphorylates phosphodiesterase-3 (PDE3) (Figure 1) [62,63].
Consequently, neither band 3 protein is dephosphorylated nor is PDE3 blocked to hydrolyze cyclic
adenosine triphosphate (cAMP) (Figure 2) [63,64]. It was evidenced that the AChE–ACh enzyme
active complex, joined with the Gαi protein, inhibits adenylyl cyclase (AC) making it unable to generate
cAMP from adenosine triphosphate (Figure 1) [17]. Another in vitro study showed that, by inducing
active protein conformations in erythrocyte AChE, by band 3 phosphorylation, the NO efflux from
erythrocytes increases (Figure 2) [65].
The NO efflux measurements from erythrocytes are based on the ACh signal transduction
pathway through the AChE–ACh active enzyme complex in active conformation, associated with Gαi
protein/AC, the phosphorylation of band 3 protein (PTK), PKC and PI3K/PDE3 proteins, and cAMP
molecules (Figure 2) [17,61,64–66].
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Figure 2. Schematic representation of the AChE–ACh active complex transduction pathway of the NO
efflux from human erythrocytes supported by in vitro studies, as explained in the text [17,61,64–66].
Studies in vivo with erythrocyte suspensions were also done either in the presence of velnacrine
or timolol, which are, respectively, strong and moderate AChE inhibitors [17,61,63,67,68]. In the
presence of velnacrine, the efflux of NO from erythrocytes is lower than that in the presence of ACh;
meanwhile, at variance, GSNO and peroxinitrite concentrations quantified in erythrocytes under the
AChE–velnacrine inactive enzyme complex were higher than those obtained in the presence of the
erythrocyte AChE–ACh complex [63,66]. The erythrocyte band 3 protein phosphorylation was absent
in erythrocytes under the presence of velnacrine [63]. It was also evidenced by an in vivo study that
AChE active or less active molecular conformations induces an increase or decrease in NO efflux from
erythrocytes, respectively [69].
When hyperfibrinogenemia is mimicked in vitro, the amount of NO efflux from erythrocytes increases,
depending on band 3 protein phosphorylation and low cAMP levels (Figure 3) [70–73]. It was
evidenced that, in the same model of hyperfibrinogenemia, the NO efflux returns to normal levels in
the presence of ACh, showing its dependence on AChE conformational states. This influence results
from the fibrinogen binding to CD47 of RH complex, associated with Gαi protein, which influences
the membrane enzyme AChE molecular conformational states (Figure 3A) [73].
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Previous studies under soluble fibrinogen at physiological concentration evidence a lower NO
efflux from erythrocytes, which indicates the scavenger RBCs’ ability, confirmed by the increased of
GSNO levels [74].
When the inhibitor of the erythrocyte Casein Kinase 2 (a cytosol protein that phosphorylates band
3 protein) is present in the erythrocytes suspensions at high fibrinogen concentration, the NO efflux is
maintained as normal, confirming the dependence on band 3 phosphorylation [75,76].
Interestingly, the forskolin, an activator of the AC enzyme, normalizes the levels of NO efflux
from erythrocytes in an in vitro model of hyperfibrinogenemia, and it is nowadays used to alleviate
symptoms of glaucoma [77,78]. Glaucoma patients present an increase in nitrogen reactive species in
aqueous humor, and the NO efflux from their erythrocytes is higher than that in healthy humans [12,79].
Therefore, one possible explanation for the therapeutic success of forskolin is the ability of erythrocytes
to preserve NO, preventing it from combining with oxygen and generating reactive species formation.
This is a clue to be explored in patients taking forskolin medication, where high levels of fibrinogen
have been observed.
5. Conclusions
The erythrocyte membrane AChE’s enzyme activity values are implicated as a biomarker
of membrane integrity (normal), aging (lower), gender (higher in females than in males),
inflammation (higher), neurotoxicity (higher), and pesticide poisoning (higher). The erythrocyte AChE
is used as diagnostic marker in Hirschsprung’s disease. The active state of AChE is modulated by the
membrane band 3 protein phosphorylation, meaning that this enzyme activity can be manipulated
from inside the erythrocytes.
Erythrocyte AChE is a biomarker of inflammation and is involved in the white blood cells
approaches to the endothelial vessel wall and in the production of pro-inflammatory cytokines.
At microcirculation, blood flow through small vessels favors gas exchanges, such as the exchange
between oxygen and nitric oxide with carbon dioxide, delivers nutrients metabolites, and removes
waste products. Erythrocytes deliver NO in tissues with lower oxygen partial pressure (PaO2) and
scavenge it at high PaO2 through the band 3 protein [80]. The ability of erythrocytes to deliver or
retain NO depends of the membrane integrity, of the AChE activation state and of its molecular
protein conformations.
The signal transduction pathways associated with NO mobilization in erythrocytes were described
under the influence of the endogenous plasma compounds, namely, ACh and fibrinogen, whose levels
increase in inflammation. There are specific key points in those pathways where activators or inhibitor
molecules of AChE, PTK, PTP, AC, PDE3 and PKC change the NO efflux from erythrocytes, which,
in the future, might be considered as therapeutic targets in vascular inflammatory diseases.
It is mandatory to highlight the new function for erythrocyte enzyme membrane AChE acting as
receptor for hydrophilic blood circulating molecules in the NO signal transduction pathway.
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